CCL5: A double-edged sword in host defense against the hepatitis C virus

International Reviews of Immunology

Volumn 30, Issue 5-6, 2011, Pages 366-378

  Katsounas, Antonios ^a   Schlaak, Joerg F ^a   Lempicki, Richard A ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SAIC FREDERICK INC   (United States)

Author keywords

CCL5 (RANTES); Hepatitis C; Liver Fibrosis

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN E2; GAMMA INTERFERON; RANTES;

BLOOD; CHEMOTAXIS; GENE EXPRESSION; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; STELLATE CELL;

CHEMOKINE CCL5; HEPACIVIRUS; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 80755130163     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.593105     Document Type: Review

References (105)

1. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75:7059-7066. (Pubitemid 32641593)
2. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163:6236-6243.
3. Lechner F, Gruener NH, Urbani S, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30:2479-2487.
4. Lechner F, Cuero, AL, Kantzanou M, Klenerman P. Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers. RevMed Virol. 11:11-22.
5. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001;75:5550-5558. (Pubitemid 32488148)
6. SchrumS, Probst P, Fleischer B, Zipfel PF. Synthesis of the CC-chemokinesMIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol. 1996;157:3598-3604. (Pubitemid 126449174)
7. Grayson MH, Holtzman MJ. Chemokine complexity: the case for CCL5. Am J Respir Cell Mol Biol. 2006; 35:143-146. (Pubitemid 44175312)
8. Stanford MM, Issekutz TB.The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J Leukoc Biol. 2003;74:791-799. (Pubitemid 38040356)
9. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003; 37:1043-1055. (Pubitemid 36538681)
10. Friedman SL.Hepatic stellate cells: protean,multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88:125-172.
11. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol. 2003;285:G949-G958. (Pubitemid 37310074)
12. Nischalke HD, Nattermann J, Fischer HP, Sauerbruch T, Spengler U, Dumoulin FL. Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm. 2004;13:357-359. (Pubitemid 40018370)
13. Apolinario A,Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationshipwith the histological activity of liver disease. AmJGastroenterol. 2002;97:2861-2870. (Pubitemid 35265441)
14. Kusano F, Tanaka Y, Marumo F, Sato C. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest. 2000;80:415-422. (Pubitemid 30167801)
15. Wei XQ, Wen ZF, Zheng FP, Yao JL. [Changes of RANTES levels in livers of patients with chronic hepatitis B: the clinical significance and the possible mechanisms]. Zhonghua Gan Zang Bing Za Zhi. 2007;15:585-588.
16. Katsounas A, Trippler M,Wang B, et al. CCL5mRNA is aMarker for early fibrosis in chronic hepatitis C and is regulated by Interferon-α therapy and Toll-like receptor 3 signaling. J ViralHepat. In press.
17. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
18. Neuman MG, Benhamou JP, Marcellin P, et al. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res. 2007;149:126-136.
19. Berres ML, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010;120:4129-4140.
20. Leifeld L, Dumoulin FL, Purr I, et al. Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol. 2003;199:335-344. (Pubitemid 36266856)
21. Shebl FM, Pinto LA, Garcia-Pineres A, et al. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19:978-981.
22. Lin YU, Liu CC, Chuang JI, et al. Involvement of oxidative stress, NF-IL-6, and RANTES expression in dengue-2-virus-infected human liver cells. Virology. 2000;276:114-126.
23. Matikainen S, Pirhonen J, Miettinen M, et al. Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages. Virology. 2000;276:138-147.
24. Matsukura S, Kokubu F, KuboH, et al. Expression of RANTES by normal airway epithelial cells after influenza virus A infection. AmJ Respir CellMol Biol. 1998;18:255-264. (Pubitemid 128355199)
25. Soo HM, Garzino-Demo A, Hong W, et al. Expression of a full-length hepatitis C virus cDNA upregulates the expression of CC chemokines MCP-1 and RANTES. Virology. 2002;303:253-277. (Pubitemid 36069190)
26. Thomas LH, Friedland JS, Sharland M, Becker S. Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B alpha. J Immunol. 1998;161:1007-1016. (Pubitemid 28323569)
27. Genin P, Algarte M, Roof P, Lin R, Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors. J Immunol. 2000; 164:5352-5361. (Pubitemid 30305215)
28. Miller K,McArdle S, GaleMJ Jr, et al. Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res. 2004;24:391-402. (Pubitemid 38998788)
29. Losana G, Bovolenta C, Rigamonti L, et al. IFN-gamma and IL-12 differentially regulate CCchemokine secretion and CCR5 expression in human T lymphocytes. J Leukoc Biol. 2002; 72:735-742. (Pubitemid 36277845)
30. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL- 12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL- 4-producingThcells. J ExpMed. 1993;177:1199-1204. (Pubitemid 23097410)
31. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346:1006-1007.
32. Fan XG, Liu WE, Li CZ, et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection.Mediators Inflamm.1998;7:295-297. (Pubitemid 28419525)
33. Kobayashi K, Ishii M, Igarashi T, et al. Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C. J Gastroenterol. 1998;33:500-507. (Pubitemid 28376979)
34. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 1997;25:449-458. (Pubitemid 27069071)
35. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol. 1997;159:1012-1018. (Pubitemid 127484258)
36. Rosen HR, Miner C, Sasaki AW, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35:190-198. (Pubitemid 34032560)
37. Sobue S, Nomura T, Ishikawa T, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol. 2001;36:544-551. (Pubitemid 32791841)
38. Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat. 2004;11:519-526. (Pubitemid 39486615)
39. Solari R, Offord RE, Remy S, et al. Receptor-mediated endocytosis of CC-chemokines. J Biol Chem. 1997;272:9617-9620. (Pubitemid 27171618)
40. Ulsenheimer A, Gerlach JT, Gruener NH, et al. Detection of functionally altered hepatitis C virusspecific CD4 T cells in acute and chronic hepatitis C. Hepatology.2003;37:1189-1198. (Pubitemid 36538697)
41. Marfaing-Koka A, Devergne O, Gorgone G, et al. Regulation of the production of the RANTES chemokine by endothelial cells: synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol. 1995;154:1870-1878.
42. Zeremski M, Petrovic LM, Talal AH.The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat. 2007;14:675-687. (Pubitemid 47414927)
43. HariharanD,Douglas SD, Lee B, Lai JP,CampbellDE,HoWZ. Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes. Blood. 1999; 93:1137-1144. (Pubitemid 29076127)
44. Zella D, Barabitskaja O, Burns JM, et al. Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells. Blood. 1998; 91:4444-4450. (Pubitemid 28270289)
45. Maldonado-Lopez R, Maliszewski C, Urbain J, Moser M. Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol. 2001;167:4345-4350. (Pubitemid 32954310)
46. Kanda T, Steele R, Ray R, Ray RB. Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice. J Virol. 2009;83:8463-8469.
47. Pelchen-Matthews A, Signoret N, Klasse PJ, Fraile-Ramos A, Marsh M. Chemokine receptor trafficking and viral replication. Immunol Rev. 1999;168:33-49. (Pubitemid 29276671)
48. Lichterfeld M, Leifeld L, Nischalke HD, et al. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patientswith chronic hepatitis C infection. J Infect Dis. 2002;185:1803-1807. (Pubitemid 34615477)
49. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003; 38:1468-1476. (Pubitemid 37466973)
50. Promrat K, Liang TJ. Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? Hepatology. 2003;38:1359-1362. (Pubitemid 37466960)
51. Lechner F,WongDK,Dunbar PR, et al.Analysis of successfulimmune responses in persons infected with hepatitis C virus. J ExpMed. 2000;191:1499-1512. (Pubitemid 30257347)
52. ThimmeR,Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV.Determinants of viral clearance and persistence during acute hepatitis C virus infection. J ExpMed. 2001;194:1395-1406. (Pubitemid 33081515)
53. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008;14:7149-159.
54. Bertoletti A,MainiMK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol. 2000; 12:403-408. (Pubitemid 30410344)
55. Kim JJ, Yang JS,Dentchev T,Dang K,WeinerDB. Chemokine gene adjuvants canmodulateimmune responses induced by DNA vaccines. J Interferon Cytokine Res. 2000;20:487-498. (Pubitemid 30414231)
56. Promrat K,McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003; 124:352-360. (Pubitemid 36169252)
57. An p, Nelson gw, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A. 2002;99:10002-10007. (Pubitemid 34831162)
58. Wasmuth HE, Werth A, Mueller T, et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology. 2004;40:327-334. (Pubitemid 39062850)
59. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000;14:2671-2678. (Pubitemid 32118720)
60. Navratilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006;150:191-204.
61. Afford SC, Fisher NC, Neil DA, et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol. 1998;186:82-89. (Pubitemid 28407492)
62. Zimmermann HW, Seidler S, Nattermann J, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 5:e11049.
63. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 1996;24:759-765. (Pubitemid 26334270)
64. Leroy V, Vigan I, Mosnier JF, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology. 2003;38:829-841. (Pubitemid 37221666)
65. Tran A, Yang G, Doglio A, et al. Phenotyping of intrahepatic and peripheral blood lymphocytes in patients with chronic hepatitis C. Dig Dis Sci. 1997;42:2495-500. (Pubitemid 28103786)
66. Khakoo SI, Soni PN, Savage K, et al. Lymphocyte andmacrophage phenotypes in chronic hepatitis C infection: correlation with disease activity. Am J Pathol. 1997;150:963-970. (Pubitemid 27106168)
67. Barnaba V, Franco A, Paroli M, et al. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol. 1994;152:3074-3087.
68. Sun QL, Ran W. Review of cytokine profiles in patients with hepatitis. World J Gastroenterol.2004; 10:1709-1715. (Pubitemid 38931191)
69. Dumoulin FL, Bach A, Leifeld L, et al. Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. J Infect Dis. 1997;175:681-685. (Pubitemid 27086175)
70. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J ExpMed.1998; 187:129-134. (Pubitemid 28044828)
71. Loetscher P, UguccioniM, Bordoli L, et al. CCR5 is characteristic ofTh1 lymphocytes. Nature.1998; 391:344-345.
72. Qin S, Rottman JB,Myers P, et al.The chemokine receptors CXCR3 and CCR5mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101:746-754. (Pubitemid 28096070)
73. Seki E,DeMinicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009; 119:1858-1870.
74. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218. (Pubitemid 40385459)
75. Kisseleva T,Brenner DA. Is it the end of the line for theEMT?Hepatology 2011May;53(5):1433-1435.
76. Dranoff JA,Wells RG. Portal fibroblasts: underappreciatedmediators of biliary fibrosis.Hepatology. 2010 Apr;51(4):1438-44. Review.
77. Bronfenmajer S, Schaffner F, Popper H. Fat-storing cells (lipocytes) in human liver. Arch Pathol. 1966;82:447-453.
78. Bonacchi A, Petrai I,Defranco RM, et al.Thechemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology. 2003;125:1060-1076. (Pubitemid 37193453)
79. Marra F, Pinzani M. Role of hepatic stellate cells in the pathogenesis of portal hypertension.Nefrologia. 2002;22 (Suppl 5):34-40.
80. Knittel T,Dinter C, KoboldD, et al. Expression and regulation of cell adhesionmolecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am J Pathol. 1999;154:153-167. (Pubitemid 29031623)
81. Shibuya K, Robinson D, Zonin F, et al. IL-1 alpha and TNF-alpha are required for IL-12-induced development ofTh1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. J Immunol. 1998;160:1708-1716. (Pubitemid 28106456)
82. Brun P, Castagliuolo I, Pinzani M, Palu G,Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2005;289:G571-G578. (Pubitemid 41216395)
83. Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44:534-541. (Pubitemid 29169954)
84. Wang B, Trippler M, Pei R, et al. Toll-like receptor activated human andmurine hepatic stellate cells are potent regulators of hepatitis C virus replication. J Hepatol. 2009 Dec;51(6):1037-1045.
85. Kuntzen T, Tural C, Li B, et al. IntrahepaticmRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS. 2008;22:203-210.
86. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497. (Pubitemid 32173638)
87. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805. (Pubitemid 40693195)
88. Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB. Liver-infiltrating lymphocytes in end-stage hepatitisCvirus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol. 2003;38:67-75. (Pubitemid 36078526)
89. Parker GA, Picut CA. Liver immunobiology. Toxicol Pathol 2005;33:52-62. (Pubitemid 40216804)
90. Poynard T, Afdhal NH. Perspectives on fibrosis progression in hepatitis C: an a la carte approach to risk factors and staging of fibrosis. Antivir Ther. 2010;15(3):281-291.
91. Brinkmann V,Geiger T, Alkan S,HeusserCH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J ExpMed. 1993;178:1655-1663. (Pubitemid 23318444)
92. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology.1996; 24:6-9. (Pubitemid 26249404)
93. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine. 1998; 10:635-644. (Pubitemid 28367897)
94. Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol. 2003;64:497-504. (Pubitemid 36504689)
95. Vertuani S, Bazzaro M, Gualandi G, et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol. 2002; 32:144-154. (Pubitemid 34092832)
96. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific Tcell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000; 118:346-355. (Pubitemid 30067508)
97. Cremer I, Ghysdael J, Vieillard V. A non-classical ISRE/ISGF3 pathway mediates induction of RANTES gene transcription by type I IFNs. FEBS Lett. 2002;511:41-45. (Pubitemid 34127820)
98. Cremer I, Vieillard V,DeMaeyer E. Retrovirally mediated IFN-beta transduction ofmacrophages induces resistance toHIV, correlatedwith up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. J Immunol. 2000;164:1582-1587. (Pubitemid 30067277)
99. Sanda C, Weitzel P, Tsukahara T, et al. Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res. 2006; 26:462-472. (Pubitemid 44061086)
100. Zimmerer JM, Lesinski GB, Radmacher MD, Ruppert A, Carson WE 3rd. STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. Cancer Immunol Immunother. 2007;56:1845-1852. (Pubitemid 47313088)
101. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001; 112:174-180.
102. Manns MP,McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
103. Yang YF, Tomura M, Iwasaki M, et al. IFN-alpha acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. J Clin Immunol. 2001; 21:402-409. (Pubitemid 34017074)
104. Foster GR,Masri SH, David R, et al. IFN-alpha subtypes differentially affect human T cellmotility. J Immunol. 2004;173:1663-1670. (Pubitemid 38971597)
105. Lempicki RA, SJ, Masur H, Polis MA, Kottilil S. Genome-wide single polymorphism analysis identifies a unique CCL-5 haplotype in HIV/HCV co-infected non-responders to pegylated interferon (peg-IFN) and ribavirin (RBV) therapy [Abstract]. Hepatology. 2009; 50(Suppl):690A.